BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Stock Rated "Moderate Buy" by Wall Street Brokerages

Key Points

• Analysts rate BioCryst a “Moderate Buy”: Six of nine covering analysts recommend buying, two rate it hold and one recommends selling. The average 12-month price target is $20.75.
• Latest reported quarter beat expectations: BioCryst posted EPS of $0.30 versus a $0.15 consensus estimate, while revenue of $218.25 million topped forecasts and increased 33.6% year over year.
• Institutional investors own 85.88% of the company’s shares. BCRX opened at $8.57, within its reported 52-week range of $6.23 to $11.22.

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) have earned an average recommendation of "Moderate Buy" from the nine analysts that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and six have given a buy recommendation to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $20.75.

A number of equities research analysts recently issued reports on BCRX shares. Wall Street Zen raised shares of BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Saturday, October 24th. Royal Bank Of Canada cut shares of BioCryst Pharmaceuticals from an "outperform" rating to a "sector perform" rating and reduced their price objective for the stock from $13.00 to $11.00 in a research report on Thursday, September 10th. Needham & Company LLC reaffirmed a "buy" rating and set a $16.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, September 8th. JPMorgan Chase & Co. upped their price target on shares of BioCryst Pharmaceuticals from $12.00 to $13.00 and gave the stock a "neutral" rating in a research report on Wednesday, September 30th. Finally, Weiss Ratings cut BioCryst Pharmaceuticals from a "hold (c)" rating to a "sell (d-)" rating in a report on Tuesday, September 22nd.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Nykredit A S purchased a new stake in BioCryst Pharmaceuticals during the 2nd quarter valued at about $27,000. IFP Advisors Inc lifted its position in BioCryst Pharmaceuticals by 2,515.3% during the second quarter. IFP Advisors Inc now owns 3,243 shares of the biotechnology company's stock worth $32,000 after buying an additional 3,119 shares in the last quarter. Allworth Financial LP acquired a new position in BioCryst Pharmaceuticals during the second quarter worth $52,000. Hilltop Holdings Inc. purchased a new stake in BioCryst Pharmaceuticals in the 1st quarter valued at $98,000. Finally, Sterling Capital Management LLC increased its stake in shares of BioCryst Pharmaceuticals by 1,373.8% in the 3rd quarter. Sterling Capital Management LLC now owns 12,056 shares of the biotechnology company's stock worth $100,000 after acquiring an additional 11,238 shares during the last quarter. Hedge funds and other institutional investors own 85.88% of the company's stock.

BioCryst Pharmaceuticals Stock Performance

Shares of NASDAQ BCRX opened at $8.57 on Wednesday. The company has a market capitalization of $2.19 billion, a PE ratio of -5.71 and a beta of 0.55. The company's fifty day moving average price is $8.58 and its 200 day moving average price is $8.74. BioCryst Pharmaceuticals has a 1 year low of $6.23 and a 1 year high of $11.22.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.30 EPS for the quarter, beating analysts' consensus estimates of $0.15 by $0.15. BioCryst Pharmaceuticals had a negative return on equity of 86.89% and a negative net margin of 40.90%. The business had revenue of $218.25 million during the quarter, compared to analysts' expectations of $183.28 million. During the same period in the previous year, the business earned $0.15 earnings per share. The business's revenue was up 33.6% compared to the same quarter last year. On average, equities analysts expect that BioCryst Pharmaceuticals will post -2.28 EPS for the current year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a biotechnology company focused on developing and commercializing oral medicines for rare and serious diseases. The company uses structure-based drug design and small-molecule research to develop therapies intended to address conditions with limited treatment options.

BioCryst's primary commercial product is Orladeyo (berotralstat), an oral medication used to prevent hereditary angioedema attacks in adults and pediatric patients aged 12 and older. The company also maintains a pipeline of investigational therapies for complement-mediated diseases and other rare disorders, including programs designed to inhibit components of the complement system.

Founded in 1986 and headquartered in Durham, North Carolina, BioCryst has historically conducted research and commercial activities in the United States and worked with international partners to make its products available in additional markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.